{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:22:04Z","timestamp":1758709324725},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T00:00:00Z","timestamp":1509926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00108-017-0347-4","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T13:23:53Z","timestamp":1509974633000},"page":"105-112","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Moderne Therapie der prim\u00e4r bili\u00e4ren Cholangitis"],"prefix":"10.1007","volume":"59","author":[{"given":"C. P.","family":"Strassburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"347_CR1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","volume":"31","author":"P Angulo","year":"2000","unstructured":"Angulo P, Jorgensen RA, Keach JC et\u00a0al (2000) Oral budesonide in the treatment of patients with primary biliary cirrhosis with a\u00a0suboptimal response to ursodeoxycholic acid. Hepatology 31:318\u2013323","journal-title":"Hepatology"},{"issue":"5","key":"347_CR2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jhep.2015.06.031","volume":"63","author":"U Beuers","year":"2015","unstructured":"Beuers U, Gershwin ME, Gish RG et\u00a0al (2015) Changing nomenclature for PBC: from \u201acirrhosis\u2018 to \u201acholangitis\u2018. J\u00a0Hepatol 63(5):1285\u20131287. \n                        https:\/\/doi.org\/10.1016\/j.jhep.2015.06.031","journal-title":"J Hepatol"},{"key":"347_CR3","unstructured":"Bundes\u00e4rztekammer (2017) Richtlinien zur Transplantationsmedizin. \n                        http:\/\/www.bundesaerztekammer.de\/richtlinien\/richtlinien\/transplantationsmedizin\n                        \n                    . Zugegriffen: 27.09.2017"},{"issue":"3","key":"347_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","volume":"144","author":"M Carbone","year":"2012","unstructured":"Carbone M, Mells G, Pells G et\u00a0al (2012) Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 144(3):560\u2013569.e7. \n                        https:\/\/doi.org\/10.1053\/j.gastro.2012.12.005","journal-title":"Gastroenterology"},{"key":"347_CR5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouilleres O, Poupon R (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55:1361\u20131367","journal-title":"J. Hepatol."},{"issue":"1","key":"347_CR6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-8278(17)30442-7","volume":"66","author":"C Corpechot","year":"2017","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, Guyader D, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledhingen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Gaouar F, Simon T, Poupon R (2017) A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso) J Hepatology 66(1):89","journal-title":"J Hepatology"},{"key":"347_CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"EASL","year":"2017","unstructured":"EASL (2017) EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J\u00a0Hepatol 67:145\u2013172","journal-title":"J Hepatol"},{"key":"347_CR8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1586\/17474124.2016.1121810","volume":"10","author":"A Floreani","year":"2016","unstructured":"Floreani A, Sun Y, Zou ZS et\u00a0al (2016) Proposed therapies in primary biliary cholangitis. Expert Rev Gastroenterol Hepatol 10:371\u2013382","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"347_CR9","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","volume":"102","author":"Y Gong","year":"2007","unstructured":"Gong Y, Huang Z, Christensen E et al (2007) Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 102:1799\u20131807","journal-title":"Am. J. Gastroenterol."},{"key":"347_CR10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","volume":"354","author":"J Goulis","year":"1999","unstructured":"Goulis J, Leandro G, Burroughs AK (1999) Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a\u00a0meta-analysis. Lancet 354:1053\u20131060","journal-title":"Lancet"},{"key":"347_CR11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield GM, Mason A, Luketic V et\u00a0al (2015) Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148:751\u2013761","journal-title":"Gastroenterology"},{"key":"347_CR12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","volume":"25","author":"DE Jones","year":"2007","unstructured":"Jones DE, Newton JL (2007) An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 25:471\u2013476","journal-title":"Aliment Pharmacol Ther"},{"key":"347_CR13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EM Kuiper","year":"2009","unstructured":"Kuiper EM, Hansen BE, de Vries RA et\u00a0al (2009) Improved prognosis of patients with primary biliary cirrhosis that have a\u00a0biochemical response to ursodeoxycholic acid. Gastroenterology 136:1281\u20131287","journal-title":"Gastroenterology"},{"key":"347_CR14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","volume":"52","author":"EM Kuiper","year":"2010","unstructured":"Kuiper EM, van Erpecum KJ, Beuers U et al (2010) The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a\u00a0double-blind, randomized, placebo-controlled trial. Hepatology 52:1334\u20131340","journal-title":"Hepatology"},{"key":"347_CR15","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","volume":"147","author":"WJ Lammers","year":"2014","unstructured":"Lammers WJ, van Buuren HR, Hirschfield GM et al (2014) Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147:1338\u20131349","journal-title":"Gastroenterology"},{"key":"347_CR16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0140-6736(87)91812-5","volume":"2","author":"U Leuschner","year":"1987","unstructured":"Leuschner U, Kurtz W (1987) Treatment of primary biliary cirrhosis and cholestatic disorders with ursodeoxycholic acid. Lancet 2:508","journal-title":"Lancet"},{"key":"347_CR17","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","volume":"117","author":"M Leuschner","year":"1999","unstructured":"Leuschner M, Maier KP, Schlichting J et al (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a\u00a0prospective double-blind trial. Gastroenterology 117:918\u2013925","journal-title":"Gastroenterology"},{"key":"347_CR18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R et\u00a0al (2009) Primary biliary cirrhosis. Hepatology 50:291\u2013308","journal-title":"Hepatology"},{"key":"347_CR19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","volume":"45","author":"MJ Mayo","year":"2007","unstructured":"Mayo MJ, Handem I, Saldana S et al (2007) Sertraline as a\u00a0first-line treatment for cholestatic pruritus. Hepatology 45:666\u2013674","journal-title":"Hepatology"},{"key":"347_CR20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","volume":"58","author":"GF Mells","year":"2013","unstructured":"Mells GF, Pells G, Newton JL et al (2013) Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 58:273\u2013283","journal-title":"Hepatology"},{"key":"347_CR21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G et al (2016) A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N\u00a0Engl J Med 375:631\u2013643","journal-title":"N Engl J Med"},{"key":"347_CR22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares A, Caballeria L, Rodes J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130:715\u2013720","journal-title":"Gastroenterology"},{"key":"347_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2013.02.019","volume":"59","author":"G Pells","year":"2013","unstructured":"Pells G, Mells GF, Carbone M et al (2013) The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol 59:67\u201373","journal-title":"J. Hepatol."},{"key":"347_CR24","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"RE Poupon","year":"1991","unstructured":"Poupon RE, Balkau B, Eschwege E et al (1991) A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 324:1548\u20131554","journal-title":"N. Engl. J. Med."},{"key":"347_CR25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"RE Poupon","year":"1997","unstructured":"Poupon RE, Lindor KD, Cauch-Dudek K et al (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113:884\u2013890","journal-title":"Gastroenterology"},{"key":"347_CR26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/liv.12560","volume":"35","author":"C Quarneti","year":"2015","unstructured":"Quarneti C, Muratori P, Lalanne C et\u00a0al (2015) Fatigue and pruritus at onset identify a\u00a0more aggressive subset of primary biliary cirrhosis. Liver Int 35:636\u2013641","journal-title":"Liver Int"},{"key":"347_CR27","first-page":"Cd000551","volume":"12","author":"JS Rudic","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN et\u00a0al (2012) Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 12:Cd551","journal-title":"Cochrane Database Syst Rev"},{"key":"347_CR28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14656566.2014.873404","volume":"15","author":"MG Silveira","year":"2014","unstructured":"Silveira MG, Lindor KD (2014) Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother 15:365\u2013372","journal-title":"Expert Opin Pharmacother"},{"key":"347_CR29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/13543784.2017.1371135","volume":"26","author":"MG Silveira","year":"2017","unstructured":"Silveira MG, Lindor KD (2017) Investigational drugs in phase II clinical trials for primary biliary cholangitis. Expert Opin Investig Drugs 26:1115\u20131121","journal-title":"Expert Opin Investig Drugs"},{"key":"347_CR30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00108-003-1127-x","volume":"45","author":"CP Strassburg","year":"2004","unstructured":"Strassburg CP, Manns MP (2004) Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy. Internist (Berl) 45:16\u201326","journal-title":"Internist (Berl)"},{"key":"347_CR31","volume-title":"S2k Leitlinie Autoimmune Lebererkrankungen. DGVS Leitlinien","author":"CP Strassburg","year":"2017","unstructured":"Strassburg CP, Beckebaum S, Geier A et\u00a0al (2017) S2k Leitlinie Autoimmune Lebererkrankungen. DGVS Leitlinien. \n                        www.dgvs.de\/leitlinien\n                        \n                    . Zugegriffen: 27.09.2017"},{"key":"347_CR32","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","volume":"102","author":"P Tandon","year":"2007","unstructured":"Tandon P, Rowe BH, Vandermeer B et al (2007) The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 102:1528\u20131536","journal-title":"Am J Gastroenterol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-017-0347-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0347-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0347-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T16:37:37Z","timestamp":1516034257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-017-0347-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1007\/s00108-017-0347-4","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]}}}